“Article: Updated results of the phase III COLUMBUS trial further solidify BRAF/MEK combinations as standard of care for BRAF-mutated advanced melanoma” has been added to your cart. View cart

Article: P18 Ibrutinib, the first available BTK inhibitor: single centre experience

€3.03

SKU: product-article-15297 Category: General

Description
Reviews (0)

Description

P18 Ibrutinib, the first available BTK inhibitor: single centre experience

Reviews

There are no reviews yet.

Be the first to review “Article: P18 Ibrutinib, the first available BTK inhibitor: single centre experience”

You must be logged in to post a review.

Top

Article: P18 Ibrutinib, the first available BTK inhibitor: single centre experience

Description

Reviews

Related products

Article: Highlights in respiratory oncology

Article: Highlights in urologic cancer

Article: Calendar of events

Article: Highlights in breast cancer